Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | What to look out for at ASCO GI 2023

Changhoon Yoo • 19 Jan 2023
ASCO GI 2023
Gastrointestinal Cancer Liver Cancer

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, provides an overview of what to look forward to at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including novel advances in the management of hepatocellular carcinoma (HCC). This interview took place at the ASCO 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Changhoon Yoo

1:15
REGONEXT: 2L regorafenib in patients with unresectable HCC who have progressed on atezo-bev
Changhoon Yoo • 18 Jan 2024
1:32
Sequencing therapies in hepatocellular carcinoma
Changhoon Yoo • 18 Jan 2024
1:34
Brightline-2: brigimadlin as a 2L treatment for advanced cancers with MDM2 amplification and wtTP53
Changhoon Yoo • 18 Jan 2024
0:33
Advancing precision medicine: exploring ctDNA analysis beyond rectal cancer
Changhoon Yoo • 3 Jun 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals